Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine.
Isayev O, Rausch V, Bauer N, Liu L, Fan P, Zhang Y, Gladkich J, Nwaeburu CC, Mattern J, Mollenhauer M, Rückert F, Zach S, Haberkorn U, Gross W, Schönsiegel F, Bazhin AV, Herr I.
Isayev O, et al. Among authors: bauer n.
Oncotarget. 2014 Jul 15;5(13):5177-89. doi: 10.18632/oncotarget.2120.
Oncotarget. 2014.
PMID: 25015789
Free PMC article.